106 related articles for article (PubMed ID: 18221066)
21. Enhancement of antitumor effects of 5-fluorouracil combined with ultrasound on Ehrlich ascites tumor in vivo.
Mohamed MM; Mohamed MA; Fikry NM
Ultrasound Med Biol; 2003 Nov; 29(11):1635-43. PubMed ID: 14654158
[TBL] [Abstract][Full Text] [Related]
22. Development and characterization of hyaluronic acid decorated PLGA nanoparticles for delivery of 5-fluorouracil.
Yadav AK; Agarwal A; Rai G; Mishra P; Jain S; Mishra AK; Agrawal H; Agrawal GP
Drug Deliv; 2010 Nov; 17(8):561-72. PubMed ID: 20738221
[TBL] [Abstract][Full Text] [Related]
23. In vitro and in vivo evaluation of injectable implants for intratumoral delivery of 5-fluorouracil.
Chen W; Wu Z; Yang H; Guo S; Li D; Cheng L
Pharm Dev Technol; 2014 Mar; 19(2):223-31. PubMed ID: 23432601
[TBL] [Abstract][Full Text] [Related]
24. Drug retention and distribution after intratumoral chemotherapy with fluorouracil/epinephrine injectable gel in human pancreatic cancer xenografts.
Smith JP; Kanekal S; Patawaran MB; Chen JY; Jones RE; Orenberg EK; Yu NY
Cancer Chemother Pharmacol; 1999; 44(4):267-74. PubMed ID: 10447573
[TBL] [Abstract][Full Text] [Related]
25. Development of a 5-fluorouracil-loaded PLGA microsphere delivery system by a solid-in-oil-in-hydrophilic oil (S/O/hO) novel method for the treatment of tumors.
Lin Q; Cai Y; Yuan M; Ma L; Qiu M; Su J
Oncol Rep; 2014 Dec; 32(6):2405-10. PubMed ID: 25231485
[TBL] [Abstract][Full Text] [Related]
26. Transbuccal delivery of 5-fluorouracil: permeation enhancement and pharmacokinetic study.
Dhiman MK; Dhiman A; Sawant KK
AAPS PharmSciTech; 2009; 10(1):258-65. PubMed ID: 19280347
[TBL] [Abstract][Full Text] [Related]
27. Influence of N-(o-methoxyphenyl)-maleimide on 5-fluorouracil cytotoxicity in Ehrlich (ascites) carcinoma.
Ambaye RY; Indap MA
Cancer Lett; 1991 Apr; 57(1):21-6. PubMed ID: 1902758
[TBL] [Abstract][Full Text] [Related]
28. Effect of implanted ethylene-vinyl alcohol copolymer matrices containing 5-fluorouracil on Ehrlich ascites carcinoma.
Miyazaki S; Takeuchi S; Sugiyama M; Takada M; Hosokawa M; Koga Y; Kobayashi H
J Pharm Pharmacol; 1985 Jan; 37(1):64-6. PubMed ID: 2858533
[TBL] [Abstract][Full Text] [Related]
29. Enhanced liver targeting of 5-fluorouracil using galactosylated human serum albumin as a carrier molecule.
Cai C; Zhou K; Wu Y; Wu L
J Drug Target; 2006 Feb; 14(2):55-61. PubMed ID: 16608732
[TBL] [Abstract][Full Text] [Related]
30. A 5-fluorouracil-loaded floating gastroretentive hollow microsphere: development, pharmacokinetic in rabbits, and biodistribution in tumor-bearing mice.
Huang Y; Wei Y; Yang H; Pi C; Liu H; Ye Y; Zhao L
Drug Des Devel Ther; 2016; 10():997-1008. PubMed ID: 27042001
[TBL] [Abstract][Full Text] [Related]
31. In vivo pharmacokinetics in human volunteers: oral administered guar gum-based colon-targeted 5-fluorouracil tablets.
Krishnaiah YS; Satyanarayana V; Dinesh Kumar B; Karthikeyan RS; Bhaskar P
Eur J Pharm Sci; 2003 Aug; 19(5):355-62. PubMed ID: 12907286
[TBL] [Abstract][Full Text] [Related]
32. Development of novel 5-fluorouracil carrier erythrocyte with pharmacokinetics and potent antitumor activity in mice bearing malignant ascites.
Wang GP; Guan YS; Jin XR; Jiang SS; Lu ZJ; Wu Y; Li Y; Li M; Luo F
J Gastroenterol Hepatol; 2010 May; 25(5):985-90. PubMed ID: 20546454
[TBL] [Abstract][Full Text] [Related]
33. 5-ethyl-2'-deoxyuridine, a modulator of both antitumour action and pharmacokinetics of 5-fluorouracil.
Kralovánszky J; Katona C; Jeney A; Pandi E; Noordhuis P; Erdélyi-Tóth V; Otvös L; Kovács P; Van der Wilt CL; Peters GJ
J Cancer Res Clin Oncol; 1999 Dec; 125(12):675-84. PubMed ID: 10592100
[TBL] [Abstract][Full Text] [Related]
34. Encapsulation and Systemic Delivery of 5-Fluorouracil Conjugated with Silkworm Pupa Derived Protein Nanoparticles for Experimental Lymphoma Cancer.
Reneeta NP; Thiyonila B; Aathmanathan VS; Ramya T; Chandrasekar P; Subramanian N; Prajapati VK; Krishnan M
Bioconjug Chem; 2018 Sep; 29(9):2994-3009. PubMed ID: 30089206
[TBL] [Abstract][Full Text] [Related]
35. Pharmacodynamics induced by direct electric current for the treatment of 5-fluorouracil resistant tumor: an animal experiment.
Ito K; Wong L; Ando H; Hibi K; Hidemura K; Kasai Y; Akiyama S; Nakao A
Int J Colorectal Dis; 2001 Sep; 16(5):326-30. PubMed ID: 11686532
[TBL] [Abstract][Full Text] [Related]
36. Enhancement in deposition and permeation of 5-fluorouracil through human epidermis assisted by peptide dendrimers.
Mutalik S; Shetty PK; Kumar A; Kalra R; Parekh HS
Drug Deliv; 2014 Feb; 21(1):44-54. PubMed ID: 24134794
[TBL] [Abstract][Full Text] [Related]
37. Treatment of false-negative metastatic lymph nodes by a lymphatic drug delivery system with 5-fluorouracil.
Fujii H; Horie S; Sukhbaatar A; Mishra R; Sakamoto M; Mori S; Kodama T
Cancer Med; 2019 May; 8(5):2241-2251. PubMed ID: 30945479
[TBL] [Abstract][Full Text] [Related]
38. Methotrexate loaded chitosan and chitin microspheres--in vitro characterization and pharmacokinetics in mice bearing Ehrlich ascites carcinoma.
Singh UV; Udupa N
J Microencapsul; 1998; 15(5):581-94. PubMed ID: 9743914
[TBL] [Abstract][Full Text] [Related]
39. Fabrication and characterization of matrix type transdermal patches loaded with tizanidine hydrochloride: potential sustained release delivery system.
Shahid N; Siddique MI; Razzaq Z; Katas H; Waqas MK; Rahman KU
Drug Dev Ind Pharm; 2018 Dec; 44(12):2061-2070. PubMed ID: 30081679
[TBL] [Abstract][Full Text] [Related]
40. Apigenin potentiates the antitumor activity of 5-FU on solid Ehrlich carcinoma: Crosstalk between apoptotic and JNK-mediated autophagic cell death platforms.
Gaballah HH; Gaber RA; Mohamed DA
Toxicol Appl Pharmacol; 2017 Feb; 316():27-35. PubMed ID: 28025107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
